Important Safety Information

Prescribe Keveyis

COMPLIMENTARY SUPPORT

Xeris CareConnection™: Redefining the experience for you and your patients

Learn about a range of free support services to help empower the Primary Periodic Paralysis (PPP) community.

Ensuring You and Your Patients Never Walk Alone

As The Proven Leader for PPP, we know it takes more than medication alone to manage this rare disease. That’s why helping people with PPP navigate their journey is at the center of everything we do. Our top goal is to provide comprehensive support for the PPP community, from patients to providers and beyond.

Read about our commitment

How we can help your practice

Navigating PPP treatment can feel like uncharted territory. Our team of PPP experts work with your practice and patients to ensure you aren’t alone. They can help with:

  • Insurance and coverage support: We’ve been helping patients and their providers navigate insurance coverage for years.
  • Prior authorization and claims: We provide education about prior authorization requirements and claims appeals.
  • Financial assistance: We offer information on financial assistance programs.
  • PANTHERx Pharmacist: We provide access to a pharmacist who specializes in KEVEYIS and will guide your patient as they begin and continue on treatment.

“The mentors, the patient access managers, I find them irreplaceable. It’s not just a medicine, it is encouragement. You have people to help you through this.”

Dennis, KEVEYIS Patient and PPP Mentor

How we can help your patients

Managing PPP takes more than medication alone. Through
Xeris CareConnection, each patient receives one-on-one support, including:

  • A dedicated Patient Access Manager.
  • Routine calls from a licensed pharmacist to discuss progress and treatment goals.
  • Mentorship with others who are living with PPP through PPP MentorConnect™.
  • Information about advocacy and support groups, as well as PPP programs.
Take the next step

Questions? We’re here to answer them.

Simply complete the form and a KEVEYIS
representative will be in touch.

By submitting this form, I give permission for a Xeris Pharmaceuticals® representative to contact me by the following methods, but not limited to: phone, email, or text message. I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to, mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals Terms of Use and Privacy Statement.

INDICATION AND IMPORTANT SAFETY INFORMATION — READ MORE

Indication and Important Safety Information

Indication

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

 

Important Safety Information

Contraindications

  • Hypersensitivity to dichlorphenamide or other sulfonamides
  • Concomitant use of KEVEYIS and high-dose aspirin
  • Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
  • Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy

 

Warnings and Precautions 

Hypersensitivity/Anaphylaxis/Idiosyncratic Reactions 

  • Fatalities associated with the administration of sulfonamides have occurred due to adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias.
  • Pulmonary involvement can occur in isolation or as part of a systemic reaction.
  • Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

Concomitant Use of Aspirin or Other Salicylates 

  • Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic acidosis, which can increase the risk of salicylate toxicity.
  • Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin.
  • Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with caution and carefully monitor in patients receiving low-dose aspirin.

Hypokalemia  

  • KEVEYIS increases potassium excretion and can cause hypokalemia.
  • The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline).
  • Baseline and periodic measurements of serum potassium are recommended.
  • If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

Metabolic Acidosis  

  • KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.
  • Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis.
  • Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.
  • Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.
  • If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS.

Falls  

  • KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses.
  • Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.

 

Pregnancy and Lactation 

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.  It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.

 

Adverse Reactions

The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.

 

Please see Full Prescribing Information.

Xeris

Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.

FOR HEALTHCARE PROVIDERS

OTHER

Copyright © 2024 Xeris Pharmaceuticals, Inc. All rights reserved.
US-KEV-24-00049 7/2024

Find answers

Take the next step

Get customized support for your KEVEYIS journey. Simply fill out the information and a Patient Access Manager will contact you. They will walk you through the entire process, from diagnosis to treatment and beyond.

By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.

Keveyis
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.